276
Registered trials
115
Recruiting
134
Completed trials
127
Sponsors
25
Countries
Phase III:
127
Phase II/III:
20
Phase II:
98
Phase I/II:
12
Phase III/IV:
2
Phase IV:
7
Phase I:
1
Phase I (Other):
3
Phase I (FiH):
6
Oversight events:
6 serious breaches
34 temporary halts
6 urgent safety measures
2 unexpected events
4 corrective measures
across 24 trials
View oversight register →
Indications tested
Non-small cell lung cancer
37
Non-small cell lung cancer metastatic
13
Cholangiocarcinoma
8
Non-small cell lung cancer stage IV
7
Non-small cell lung cancer stage III
6
Non-small cell lung cancer stage IIIB
5
Non-small cell lung cancer stage II
4
Non-small cell lung cancer recurrent
4
Small cell lung cancer extensive stage
3
Squamous cell carcinoma of head and neck
3
Bladder cancer
3
Diffuse large B-cell lymphoma
3
Sponsors using this IMP
AstraZeneca AB
30
Merck Sharp & Dohme LLC
30
Bristol-Myers Squibb Services Unlimited Company
11
F. Hoffmann-La Roche AG
8
Daiichi Sankyo Inc.
6
Groupe Oncologie Radiotherapie Tete Cou
6
IRCCS Istituto Nazionale Tumori Fondazione Pascale
6
Regeneron Pharmaceuticals Inc.
6
Unicancer
6
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
5
Institut Gustave Roussy
5
AbbVie Deutschland GmbH & Co. KG
4
All trials
276 total-
SIOP PNET 5 medulloblastoma Pending
Showing 1–24 of 276 trials